Literature DB >> 21620723

Quantitative proton MR spectroscopy as a biomarker of tumor necrosis in the rabbit VX2 liver tumor.

Manon Buijs1, Josephina A Vossen, Jean-Francois H Geschwind, Nouha Salibi, Li Pan, Veronica Prieto Ventura, Eleni Liapi, Kwang Hun Lee, Ihab R Kamel.   

Abstract

PURPOSE: To compare metabolic magnetic resonance (MR) imaging findings (ie, quantification of tumor choline concentration) with percentage of necrosis on pathologic examination in rabbits bearing VX2 liver tumors.
MATERIALS AND METHODS: VX2 tumors were implanted in the livers of 16 rabbits. MR imaging was performed with a 1.5-T MR scanner and extremity coil, and a hydrogen-1 ((1)H) proton MR spectroscopy ((1)H MRS) imaging protocol was used. Rabbits were euthanized immediately after imaging, and the tumor was harvested and sliced at 4-mm intervals in the axial plane. Choline concentration was calculated and was compared with the percentage of tumor necrosis on pathologic examination.
RESULTS: Mean tumor size at pathologic examination was 16 mm (range, 12-22 mm). Mean percentage of necrosis at pathologic examination was 22% (range, 4%-44%). Choline concentration showed a relatively high inverse correlation with percentage of necrosis on pathologic examination, with an r value of 0.78 (P < .002).
CONCLUSIONS: Choline concentration showed a relatively high inverse correlation with tumor necrosis on pathologic examination. Therefore, (1)H MRS may be useful to assess tumor necrosis.
Copyright © 2011 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620723      PMCID: PMC4334359          DOI: 10.1016/j.jvir.2011.03.016

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  28 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 3.  Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: a review.

Authors:  Frank Fischbach; Harald Bruhn
Journal:  Liver Int       Date:  2008-03       Impact factor: 5.828

4.  Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.

Authors:  Ihab R Kamel; Eleni Liapi; Diane K Reyes; Marianna Zahurak; David A Bluemke; Jean-François H Geschwind
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

5.  Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings.

Authors:  S G Cho; M Y Kim; H J Kim; Y S Kim; W Choi; S H Shin; K C Hong; Y B Kim; J H Lee; C H Suh
Journal:  Radiology       Date:  2001-12       Impact factor: 11.105

Review 6.  Measures of response: RECIST, WHO, and new alternatives.

Authors:  C Carl Jaffe
Journal:  J Clin Oncol       Date:  2006-07-10       Impact factor: 44.544

7.  Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience.

Authors:  Chiao-Yun Chen; Chun-Wei Li; Yu-Ting Kuo; Twei-Shiun Jaw; Ding-Kwo Wu; Jo-Chi Jao; Jui-Sheng Hsu; Gin-Chung Liu
Journal:  Radiology       Date:  2006-03-28       Impact factor: 11.105

8.  WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy.

Authors:  R J Ogg; P B Kingsley; J S Taylor
Journal:  J Magn Reson B       Date:  1994-05

9.  In vivo, high-field, 3-Tesla 1H MR spectroscopic assessment of liver fibrosis in HCV-correlated chronic liver disease.

Authors:  A Orlacchio; F Bolacchi; M Angelico; A Mancini; V Cozzolino; M Cadioli; G Simonetti
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

10.  Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference.

Authors:  P B Barker; B J Soher; S J Blackband; J C Chatham; V P Mathews; R N Bryan
Journal:  NMR Biomed       Date:  1993 Jan-Feb       Impact factor: 4.044

View more
  9 in total

1.  Extracellular pH mapping of liver cancer on a clinical 3T MRI scanner.

Authors:  Daniel Coman; Dana C Peters; John J Walsh; Lynn J Savic; Steffen Huber; Albert J Sinusas; MingDe Lin; Julius Chapiro; R Todd Constable; Douglas L Rothman; James S Duncan; Fahmeed Hyder
Journal:  Magn Reson Med       Date:  2019-11-05       Impact factor: 4.668

2.  Low-Dose CT Perfusion of the Liver using Reconstruction of Difference.

Authors:  Saeed Seyyedi; Eleni Liapi; Tobias Lasser; Robert Ivkov; Rajeev Hatwar; J Webster Stayman
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2018-03-05

Review 3.  Rabbit VX2 Liver Tumor Model: A Review of Clinical, Biology, Histology, and Tumor Microenvironment Characteristics.

Authors:  Florentina Pascale; Jean-Pierre Pelage; Michel Wassef; Saïda H Ghegediban; Jean-Pierre Saint-Maurice; Thierry De Baere; Alban Denys; Rafael Duran; Frédéric Deschamps; Olivier Pellerin; Noboru Maeda; Alexandre Laurent; Julien Namur
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

4.  Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment.

Authors:  Daniel Coman; Julius Chapiro; Lynn Jeanette Savic; Isabel Theresa Schobert; Dana Peters; John J Walsh; Fabian Max Laage-Gaupp; Charlie Alexander Hamm; Nina Tritz; Luzie A Doemel; MingDe Lin; Albert Sinusas; Todd Schlachter; James S Duncan; Fahmeed Hyder
Journal:  Clin Cancer Res       Date:  2019-10-03       Impact factor: 12.531

5.  Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.

Authors:  Johanna Maria Mijntje van Breugel; Jean-François Geschwind; Sahar Mirpour; Lynn Jeanette Savic; Xuchen Zhang; Rafael Duran; MingDe Lin; Milena Miszczuk; Eleni Liapi; Julius Chapiro
Journal:  Theranostics       Date:  2019-05-27       Impact factor: 11.556

6.  Elastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model.

Authors:  Federico Collettini; Carolin Reimann; Julia Brangsch; Julius Chapiro; Lynn Jeanette Savic; David C Onthank; Simon P Robinson; Uwe Karst; Rebecca Buchholz; Sarah Keller; Bernd Hamm; S Nahum Goldberg; Marcus R Makowski
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.379

7.  Diagnostic value of 3.0T (1)H MRS with choline-containing compounds ratio (∆CCC) in primary malignant hepatic tumors.

Authors:  Li Zhang; Xinming Zhao; Han Ouyang; Shuang Wang; Chunwu Zhou
Journal:  Cancer Imaging       Date:  2016-08-22       Impact factor: 3.909

8.  Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.

Authors:  Yewei Liu; Ting Yin; Frederik De Keyzer; Yuanbo Feng; Feng Chen; Jianjun Liu; Shaoli Song; Jie Yu; Vincent Vandecaveye; Johan Swinnen; Guy Bormans; Uwe Himmelreich; Raymond Oyen; Jian Zhang; Gang Huang; Yicheng Ni
Journal:  Oncotarget       Date:  2017-07-18

9.  Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.

Authors:  Ye-Wei Liu; Frederik De Keyzer; Yuan-Bo Feng; Feng Chen; Shao-Li Song; Johan Swinnen; Guy Bormans; Raymond Oyen; Gang Huang; Yi-Cheng Ni
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.